BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $38 to $39.
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $38 to $39.